Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Dr. Howard Fields to Join NanoViricides as Vice-President of Virology

Abstract:
International Hepatitis Expert from CDC to Manage R&D and Collaborations

Dr. Howard Fields to Join NanoViricides as Vice-President of Virology

WEST HAVEN, CT | Posted on March 24th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Howard Fields, PhD, currently a member of the Scientific Advisory Board, will join the Company as Vice President of Virology.

"We're very pleased to have Dr. Fields, a scientist of great international repute, joining us. He will guide, manage, and coordinate our extensive activities in all aspects of virology. His international experience in developing novel approaches to problems in virology, and in successfully managing multi-national collaborations amongst various agencies, will be of tremendous benefit to NanoViricides," said Eugene Seymour, MD, MPH, CEO of the Company.

Dr. Fields is a distinguished international expert in several areas of immunology, biochemistry, molecular biology, virology, and general microbiology. He has applied his knowledge to the study of viral hepatitis during an illustrious 32 year career at the Centers for Disease Control and Prevention publishing 160 manuscripts in international peer-reviewed journals and editing a book entitled "Artificial DNA". Dr. Fields pioneered research in using genetic engineering technology in the rational design of artificial antigens as targets for immunoassay development. He first joined CDC as an immunovirologist in 1976. During his thirty-two year career at the CDC, he was the Team Leader of the Assay Development and Cell Culture Team within the Division of Viral Hepatitis Center where he led the research on all hepatitis viruses including Hepatitis C Virus, and Hepatitis B Virus from 2002 until retiring recently.

"NanoViricides has developed a unique platform technology that is based on sound virological and biological principles. I am very pleased with the success of the nanoviricides drug candidates against numerous important viral diseases of public health significance. The novel host-cell-mimetic technology that Dr. Diwan invented has now culminated in the development of the Company's broad-spectrum antivirals. This technology represents an innovative and novel approach in the treatment of viral infections and I'm truly excited to be part of its future," said Dr. Fields.

At the CDC, in 1983, Dr. Fields was Chief, Molecular and Immunodiagnostic Section (MIDS), Hepatitis Branch, Division of Viral and Rickettsial Diseases. From 1990 to 1994, he was given the responsibility for the conduct of the WHO Collaborating Centre for Reference and Research on Viral Hepatitis at CDC with emphasis on technology transfer issues. Dr. Fields has been a consultant to various pharmaceutical industries including Bayer, Germany, Abbott Laboratories, Serologics, Inc., American Qualex, Eugene Tech International Inc., Nuclear Medical Laboratories, Dallas, TX, as well as Biokit, Barcelona, Spain, and Span Research Center, Surat, India. He is a member of the scientific advisory board of Cambridge Biotech, Galway, Ireland, and of NanoViricides, Inc.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, Ebola virus, and dengue fever, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

MEMS & Sensors Technology Showcase: Finalists Announced for MEMS Executive Congress US 2014 October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

Agar Scientific appoints Paul Balaş as new Technical Sales Manager October 3rd, 2014

PEN Inc. Chairman Scott Rickert Announces Company Vision, Product Priorities and Management Team: Webcast Highlights the Launch of PEN October 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE